Is it SLE?

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 2, 2002, Pages 167-180

  Maddison, Peter J ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Antinuclear antibodies; Differential diagnosis; Infection; Systemic lupus erythematosus

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; COSMETIC; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCAINAMIDE; SALAZOSULFAPYRIDINE;

ACNE; ARTHRITIS; BACTERIAL INFECTION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG MEGADOSE; FIBROMYALGIA; HEMOLYSIS; HUMAN; INFLAMMATION; LABORATORY DIAGNOSIS; LEUKOPENIA; LUPUS ERYTHEMATOSUS; LUPUS VULGARIS; LYMPHOCYTOPENIA; MIXED CONNECTIVE TISSUE DISEASE; MOUTH ULCER; ONSET AGE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PSYCHOSIS; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SEIZURE; SEROLOGY; SKIN INFECTION; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE; WITHDRAWAL SYNDROME; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; AUTOIMMUNE HEPATITIS; BEHCET DISEASE; BLOOD CELL COUNT; CONTACT DERMATITIS; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HEP 2 CELL; IMMUNOFLUORESCENCE; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; PHOTODERMATOSIS; RADIOIMMUNOASSAY; RAYNAUD PHENOMENON; ROSACEA; SARCOIDOSIS; SCREENING TEST; SEBORRHEIC DERMATITIS; SYPHILIS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; URINALYSIS; VASCULITIS; IMMUNOLOGY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEROLOGIC TESTS;

EID: 0036526747     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0219     Document Type: Review

References (67)

1. Benedek TG. Historical background of discoid and systemic lupus erythematosus. In Wallace DJ & Hahn BH (eds) Dubois' Lupus Erythematosus, 5th edn, pp 3-16. Baltimore: Williams, and Wilkins, 1997.
2. Harvey AM, Shulman LE, Tumulty PA et al. Systemic lupus erythematosus: Review of the literature and clinical analysis of 138 cases. Medicine 1954; 33: 291-437.
3. Hochberg MC, Boyd RE, Ahearn JM et al. Systemic lupus erythematosus: A review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 285-295.
4. Cervera R, Khamashta MA, Front J et al. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 1993; 72: 113-124.
5. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40: 1725-1734.
6. Levin DL, Roenigk HH, Caro WA & Lyons M. Histologic, immunofluorescent, and antinuclear antibody findings in PUVA-treated patients. Journal of the American Academy of Dermatology 1982; 6: 328-333.
7. Ward MM & Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis and Rheumatism 1989; 32: 1226-1232.
8. Jonsson H, Nived O, Sturfelt G & Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources for retrieval. British Journal of Rheumatology 1990; 29: 185-188.
9. Catoggio LJ, Skinner RP, Smith G & Maddison PJ. Systemic lupus erythematosus in the elderly: Clinical and serologic characteristics. Journal of Rheumatology 1984; 11: 175-181.
10. Holborow EJ, Weir DM & Johnson GD. A serum factor in lupus erythematosus with affinity for tissue nuclei. British Medical Journal 1957; 2: 732-736.
11. Liang MH, Meenan RF, Cathcart ES & Schur PH. A screening strategy for population studies in systemic lupus erythematosus: Series design. Arthritis and Rheumatism 1980; 23: 152-157.
12. Forslid J, Heigl Z, Johnsson J & Scheynius A. The prevalence of antinuclear antibodies in healthy young persons and adultts, comparing rat liver tissue sections with HEp-2 cells as antigen substrate. Clinical and Experimental Rheumatology 1994; 12: 137-141.
13. Fielder AHL, Walport MJ, Batchelor JR et al. Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: Importance of null alleles of C4A and C4B in determining disease susceptibility. British Medical Journal 1983; 286: 425-428.
14. Maddison PJ, Stephens C, Briggs D et al. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. Medicine 1993; 72: 103-112.
15. Harley JB & Gaither KK. Autoantibodies. Rheumatology Clinics of North America 1988; 14: 43-53.
16. Fritzler MJ & Miller JM. Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. Journal of Clinical Laboratory Analysis 1995; 9: 218-224.
17. Clough JD, Calabrese LH & Valenzuela R. The ANA profile; Quality and cost effective laboratory utilization. Cleveland Journal of Clinical Medicine 1989; 56: 245-248.
18. Slater CA, Davis RB & Shmerling RH. Antinuclear antibody testing: A study of clinical utility. Archives of Internal Medicine 1996; 156: 1421-1425.
19. Aarden LA, Lakmaker F & Feltkamp TEW. Immunology of DNA. I. The influence of reaction conditions on the Farr assay as used for the detection of anti-dsDNA. Journal of Immunological Methods 1976; 10: 39-48.
20. Aarden LA & Smeenk R. Measurements of antibodies specific for DNA. In Lefkovitis I & Pernis B (eds) Immunological Methods, vol. 2, pp 75-82. New York: Academic Press, 1981.
21. Smeenk R, Brinkman K, Van Den Brink H & Swaak T. A comparison of assays used for the detection of antibodies to DNA. Clinical Rheumatology 1990; 9: 63-73.
22. Reichlin M & Harley JB. Immune response to the RNA protein particles in systemic lupus erythematosus. A distinctive dichotomy. American Journal of Medicine 1988; 85 (supplement 6A): 350-354.
23. Van Venrooij WJ & Sillekens PTG. Small nuclear RNA associated proteins: Autoantigens in connective tissue diseases. Clinical and Experimental Rheumatology 1989; 7: 635-645.
24. Scofield RH, Farris AD, Horsfall AC & Harley JB. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis and Rheumatism 1999; 42: 199-209.
25. Arnett FC. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. Journal of Rheumatology 1988; 15: 1773-1776.
26. Asero R, Origgi L, Crespi S et al. Autoantibody to proliferating cell nuclear antigen (PCNA) in SLE: A clinical and serological study. Clinical and Experimental Rheumatology 1987; 5: 241-246.
27. Elkon KB, Bonfa E, Weissbach H & Brot N. Antiribosomal antibodies in SLE, infection, and following deliberate immunisation. Advances in Experimental Medicine and Biology 1994; 347: 81-92.
28. Burnham TK & Fine G. The immunofluorescence 'band' test for lupus erythematosus. I. Morphologic variations of localized immunoglobulins at the dermal-epidermal junction in in lupus erythematosus. Archives of Dermatology 1969; 99: 413-420.
29. Cormane RH. Band immunoglobulin in the skin of patients with chronic discoid lupus erythematosus and systemic lupus erythematosus. Lancet 1964; i: 534-535.
30. Sontheimer RD & Provost TT. Lupus erythematosus. In Sontheimer RD & Provost TT (eds) Cutaneous Manifestations of Rheumatic Diseases, pp 1-71. Baltimore: Williams and Wilkins, 1996.
31. Blaszcyk M, Jablonska S, Chorzelski TP et al. Clinical relevance of immunologic findings in cutaneous lupus erythematosus. Clinics in Dermatology 1993; 10: 399-406.
32. Maddison PJ, Provost TT & Reichlin M. Serological findings in patients with 'ANA-negative' systemic lupus erythematosus. Medicine 1981; 60: 87-94.
33. Reichlin M, Rader M & Harley JB. Autoimmune response to the Ro/SSA particle is directed to the human antigen. Clinical and Experimental Immunology 1989; 96: 373-377.
34. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in the 1980s: A survey of 570 patients. Seminars in Arthritis and Rheumatism 1991; 21: 55-64.
35. Meyer O, Piette JC, Bourgeois P et al. Antiphospholipid antibodies: A disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE): Comparison with a group of 91 patients with antinuclear antibody positive SLE. Journal of Rheumatology 1987; 14: 502-506.
36. Ferreiro JE, Reiter WM & Saldana MJ. Systemic lupus erythematosus presenting as a chronic serositis with no demonstrable antinuclear antibodies. American Journal of Medicine 1984; 76: 1100-1105.
37. LeRoy EC, Maricq HR & Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis and Rheumatism 1980; 23: 341-343.
38. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Clinical Rheumatology 2000; 14: 125-137.
39. Mosca M, Neri R & Bombardieri S. Undifferentiated connective tissue diseases (UCTD): A review of the literature and a proposal for preliminary classification criteria. Clinical and Experimental Rheumatology 1999; 17: 615-620.
40. Alarcon-Segovia D & Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In Kasukawa R & Sharp GC (eds) Mixed Connective Tissue Disease and Antinuclear Antibodies, pp 33-40. Amsterdam: Excerpta Medica, 1987.
41. Swaak AJG, Van De Brink H, Smeenk RJT et al. Incomplete lupus erythematosus: Results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology 2001; 40: 89-94.
42. Rubin RL. Drug-induced lupus. In Wallace DJ & Hahn BH (eds) Dubois' Lupus Erythematosus, 5th edn, pp 871-901. Baltimore: Williams and Wilkins, 1997.
43. Reed BR, Huff JC, Jones SK et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Annals of Internal Medicine 1985; 103: 49-51.
44. McHugh NJ. Minocycline-induced lupus and autoimmune phenomena. Lupus 1999; 8: 417-418.
45. Lawson TM, Amos N, Bulgen D & Williams BD. Minocycline-induced lupus: Clinical features and response to rechallenge. Rheumatology 2001; 40: 329-335.
46. Gunnarsson I, Kanerud L, Pettersson E et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. British Journal of Rheumatology 1997; 36: 1089-1094.
47. Provost TT, Talal N, Harley JB et al. The relationship between anti-Ro(SS-A) antibody-Sjogren's syndrome and anti-Ro(SS-A) antibody-positive lupus erythematosus. Archives of Dermatology 1988; 124: 63-71.
48. Sharp GC, Irving W, Tan E et al. Mixed connective tissue disease: An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). American Journal of Medicine 1972; 52: 148-159.
49. Black C & Isenberg DA. Mixed connective tissue disease-goodbye to all that. British Journal of Rheumatology 1992; 31: 695-700.
50. Maddison PJ. MCTD: Overlap syndromes. Clinical Rheumatology 2000; 14: 111-124.
51. Brand CA, Rowley MJ, Tait BD et al. Co-existent rheumatoid arthritis and systemic lupus erythematosus: Clinical, serological and phenotypic features. Annals of the Rheumatic Diseases 1992; 51: 173-176.
52. Panush RS, Edwards L, Longley S & Webster E. 'Rhupus' syndrome. Archives of Internal Medicine 1988; 148: 1633-1636.
53. Bennett R. The concurrence of lupus and fibromyalgia: Implications for diagnosis and management. Lupus 1997; 6: 494-499.
54. Clark S, Tindall E & Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. Journal of Rheumatology 1985; 12: 980-983.
55. Calvo-Alen J, Bastian HM, Straaton KV et al. Identification of patient subsets among those presumptively diagnosed with, referred and/or followed up for systemic lupus erythematosus at a large tertiary care centre. Arthritis and Rheumatism 1995; 38: 1475-1484.
56. Yunus MB, Hussey FX & Aldag JC. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: A controlled study. Journal of Rheumatology 1993; 20: 1557-1560.
57. Kennedy M & Felson DT. A prospective long-term study of fibromyalgia syndrome. Arthritis and Rheumatism 1996; 39: 682-685.
58. Morand EF, Miller MH, Whittingham S & Littlejohn GO. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus 1994; 3: 187-191.
59. De Clerk LS, Couttenye MM, De Broe ME & Stevens WJ. Acquired immunodeficiency mimicking Sjogren's syndrome and systemic lupus erythematosus. Arthritis and Rheumatism 1988; 31: 272-275.
60. Shatley MJ, Walker BL & McMurray RW. Lues and lupus: Syphilis mimicking systemic lupus erythematosus (SLE). Lupus 2001; 10: 299-303.
61. Feng PH & Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Annals of Rheumatic Diseases 1982; 41: 11-14.
62. Staples PJ, Gerding DN, Decker JL & Gordon RS Jr. Incidence of infections in systemic lupus erythematosus. Arthritis and Rheumatism 1974; 17: 1-10.
63. Nived O, Sturfelt G & Wollheim F. Systemic lupus erythematosus and infection: A controlled and prospective study including an epidemiological group. Quarterly Journal of Medicine 1985; 218: 271-287.
64. Ginzler E, Diamond H, Kaplan D et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis and Rheumatism 1978; 21: 37-44.
65. Pepys MB, Lanham JG & De Beer FC. C-reactive protein in SLE. Clinics in Rheumatic Diseases 1982; 8: 91-103.
66. Spronk PE, Ter Borg EJ & Kallenberg CGM. Patients with systemic lupus erythematosus and Jaccoud's arthropathy - A clinical subset with an increased C-reactive protein response. Annals of the Rheumatic Diseases 1992; 51: 385-361.
67. Ter Borg EJ, Horst G, Limburg PC et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. Journal of Rheumatology 1990; 17: 1642-1648.